Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VNN1 | O95497 | 7/20 | 0.64 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.50 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11563704 | 0.89 | VNN1 (0.64) | VNN1HDAC1NPC1RAB9AKMT2A | |
| SCHEMBL30465779 | 0.88 | VNN1 (0.70) | VNN1HDAC1NPC1RAB9AKMT2A | |
| SCHEMBL11567319 | 0.88 | ALDH1A1 (0.61) | VNN1HDAC1CA1CA2GABRA5 | |
| SCHEMBL22084214 | 0.86 | VNN1 (0.57) | VNN1HDAC1NPC1RAB9AMAPT | |
| SCHEMBL20722658 | 0.86 | CA1 (0.62) | VNN1HDAC1CA1CA2HDAC3 | |
| SCHEMBL17602245 | 0.84 | HDAC1 (0.57) | VNN1HDAC1NPC1RAB9AKMT2A | |
| SCHEMBL2308761 | 0.82 | NPC1 (0.68) | VNN1HDAC1NPC1RAB9AKMT2A | |
| SCHEMBL10255569 | 0.81 | HDAC1 (0.67) | VNN1HDAC1NPC1RAB9AKMT2A | |
| SCHEMBL16211422 | 0.81 | RAB9A (0.54) | VNN1NPC1RAB9AKMT2AMAPT | |
| SCHEMBL18424186 | 0.81 | SMN1; SMN2 (0.56) | HDAC1NPC1RAB9ACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9145354-B2 | Pharmaceutical compounds | ASTEX THERAPEUTICS LIMITED (GB) | 2015-09-29 | — | — | US | disclosed |
| US-20150051199-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2015-02-19 | — | — | US | disclosed |
| EP-2773615-A1 | PHARMACEUTICAL COMPOUNDS | Astex Therapeutics Limited (GB) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064543-A1 | PHARMACEUTICAL COMPOUNDS | ASTEX THERAPEUTICS LIMITED (GB) | 2013-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150051199-A1 | PHARMACEUTICAL COMPOUNDS | NR1H4, HAVCR2, NR1H3 | VNN1 3177/4885HDAC1 1052/4885NPC1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.